Michael S. Perry

Insider · Director · ARWR

Michael S. Perry files insider transactions with the SEC as a director of Arrowhead Research (ARWR). We hold 1 disclosed purchase or sale filed since 10 May 2006, 1 of them in the last 90 days.

Files forARWR
Disclosed buys and sells1 in all, 1 in the last 90 days
Last disclosure20 August 2026

Positions held

7 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 16 February 2012 — 18 August 2026Director · Arrowhead Research (ARWR)42 Form 4 lines · source: SEC Form 4
Filed 9 September 2020 — 21 November 2022Chief Executive Officer · Avita Therapeutics (RCEL)27 Form 4 lines · source: SEC Form 4
Filed 9 May 2019 — 22 May 2019Director · Armata Pharmaceuticals (ARMP)2 Form 4 lines · source: SEC Form 4
Filed 21 September 2015 — 22 March 2018Director · AmpliPhi Biosciences (APHB)5 Form 4 lines · source: SEC Form 4
Filed 5 February 2010 — 27 March 2012President & CMO · Poniard Pharmaceuticals (PARD)14 Form 4 lines · source: SEC Form 4
Filed 27 May 2010 — 27 May 2010Director · Targeted Genetics Corp /wa/ (TGEN.PK)1 Form 4 line · source: SEC Form 4
Filed 8 May 2006 — 29 May 2009Director · Targeted Genetics Corp /wa/ (TGEN)4 Form 4 lines · source: SEC Form 4

Everything they disclosed

95 entries, newest first — one per disclosure report, one per Form 4 line

▼ sold on the open market 11,600 shares of Arrowhead PharmaceuticalsSEC Form 420 August 2026Common Stock · traded 18 August 2026 · filed 20 August 2026
was granted 7,819 shares of Arrowhead PharmaceuticalsSEC Form 418 December 2025Common Stock · traded 16 December 2025 · filed 18 December 2025
▼ sold on the open market 16,250 shares of Arrowhead PharmaceuticalsSEC Form 49 December 2025Common Stock · traded 5 December 2025 · filed 9 December 2025
was granted 16,733 shares of Arrowhead PharmaceuticalsSEC Form 420 December 2024Common Stock · traded 18 December 2024 · filed 20 December 2024
was granted 14,987 shares of Arrowhead PharmaceuticalsSEC Form 419 December 2023Common Stock · traded 15 December 2023 · filed 19 December 2023
was granted 4,593 shares of Arrowhead Pharmaceuticals (a derivative holding)SEC Form 411 January 2023Common Stock · traded 10 January 2023 · filed 11 January 2023
was granted 7,867 shares of Arrowhead PharmaceuticalsSEC Form 411 January 2023Common Stock · traded 10 January 2023 · filed 11 January 2023
exercised options over 150,000 shares of AVITA Medical (a derivative holding)SEC Form 422 November 2022Stock Options (Right to Buy) · traded 21 November 2022 · filed 22 November 2022
exercised options over 150,000 shares of AVITA MedicalSEC Form 422 November 2022Common Stock · traded 21 November 2022 · filed 22 November 2022
▼ sold on the open market 150,000 shares of AVITA MedicalSEC Form 422 November 2022Common Stock · traded 21 November 2022 · filed 22 November 2022
was granted 3,450 shares of AVITA Medical (a derivative holding)SEC Form 46 September 2022Stock Options (Right to Buy) · traded 1 September 2022 · filed 6 September 2022
was granted 2,980 shares of AVITA MedicalSEC Form 46 September 2022Common Stock · traded 1 September 2022 · filed 6 September 2022
acquired or disposed of, other 23,754 shares of AVITA MedicalSEC Form 42 June 2022Common Stock · traded 1 June 2022 · filed 2 June 2022
was granted 3,450 shares of AVITA Medical (a derivative holding)SEC Form 425 February 2022Stock Options (Right to Buy) · traded 23 February 2022 · filed 25 February 2022
was granted 23,753 shares of AVITA MedicalSEC Form 425 February 2022Common Stock · traded 23 February 2022 · filed 25 February 2022
was granted 5,960 shares of AVITA MedicalSEC Form 425 February 2022Common Stock · traded 23 February 2022 · filed 25 February 2022
▼ sold on the open market 10,812 shares of AVITA MedicalSEC Form 425 February 2022Common Stock · traded 24 February 2022 · filed 25 February 2022
was granted 6,400 shares of Arrowhead PharmaceuticalsSEC Form 47 January 2022Common Stock · traded 7 January 2022 · filed 7 January 2022
▼ sold on the open market 2,628 shares of Arrowhead PharmaceuticalsSEC Form 44 January 2022Common Stock · traded 3 January 2022 · filed 4 January 2022
▼ sold on the open market 1,600 shares of Arrowhead PharmaceuticalsSEC Form 44 January 2022Common Stock · traded 3 January 2022 · filed 4 January 2022
▼ sold on the open market 272 shares of Arrowhead PharmaceuticalsSEC Form 44 January 2022Common Stock · traded 3 January 2022 · filed 4 January 2022
was granted 13,800 shares of AVITA Medical (a derivative holding)SEC Form 427 December 2021Stock Options (Right to Buy) · traded 22 December 2021 · filed 27 December 2021
was granted 13,800 shares of AVITA Medical (a derivative holding)SEC Form 427 December 2021Stock Options (Right to Buy) · traded 22 December 2021 · filed 27 December 2021
was granted 13,800 shares of AVITA Medical (a derivative holding)SEC Form 427 December 2021Stock Options (Right to Buy) · traded 22 December 2021 · filed 27 December 2021
was granted 23,800 shares of AVITA MedicalSEC Form 427 December 2021Common Stock · traded 22 December 2021 · filed 27 December 2021
was granted 23,820 shares of AVITA MedicalSEC Form 427 December 2021Common Stock · traded 22 December 2021 · filed 27 December 2021
was granted 23,820 shares of AVITA MedicalSEC Form 427 December 2021Common Stock · traded 22 December 2021 · filed 27 December 2021
was granted 23,754 shares of AVITA MedicalSEC Form 47 September 2021Common Stock · traded 1 September 2021 · filed 7 September 2021
▼ sold on the open market 11,220 shares of AVITA MedicalSEC Form 47 September 2021Common Stock · traded 1 September 2021 · filed 7 September 2021
▼ sold on the open market 23,000 shares of AVITA MedicalSEC Form 44 June 2021Common Stock · traded 2 June 2021 · filed 4 June 2021
was granted 9,000 shares of Arrowhead PharmaceuticalsSEC Form 45 January 2021Common Stock · traded 1 January 2021 · filed 5 January 2021
▼ sold on the open market 4,000 shares of Arrowhead PharmaceuticalsSEC Form 45 January 2021Common Stock Sold · traded 4 January 2021 · filed 5 January 2021
was granted 68,504 shares of Avita TherapeuticsSEC Form 416 September 2020Common Stock · traded 14 September 2020 · filed 16 September 2020
▼ sold on the open market 15,092 shares of Avita TherapeuticsSEC Form 416 September 2020Common Stock · traded 14 September 2020 · filed 16 September 2020
▼ sold on the open market 23,769 shares of Avita TherapeuticsSEC Form 416 September 2020Common Stock · traded 15 September 2020 · filed 16 September 2020
▼ sold on the open market 9,000 shares of Avita TherapeuticsSEC Form 416 September 2020Common Stock · traded 16 September 2020 · filed 16 September 2020
was granted 25,000 shares of Avita Therapeutics (a derivative holding)SEC Form 411 September 2020Stock Options (Right to Buy) · traded 9 September 2020 · filed 11 September 2020
was granted 83,333 shares of Avita TherapeuticsSEC Form 411 September 2020Common Stock · traded 9 September 2020 · filed 11 September 2020
▼ sold on the open market 7,128 shares of Avita TherapeuticsSEC Form 411 September 2020Common Stock · traded 10 September 2020 · filed 11 September 2020
▼ sold on the open market 20,000 shares of Avita TherapeuticsSEC Form 411 September 2020Common Stock · traded 11 September 2020 · filed 11 September 2020
exercised options over 7,000 shares of Arrowhead Pharmaceuticals (a derivative holding)SEC Form 418 May 2020Common Stock (right to buy) · traded 14 May 2020 · filed 18 May 2020
exercised options over 5,000 shares of Arrowhead Pharmaceuticals (a derivative holding)SEC Form 418 May 2020Common Stock (right to buy) · traded 14 May 2020 · filed 18 May 2020
exercised options over 15,000 shares of Arrowhead Pharmaceuticals (a derivative holding)SEC Form 418 May 2020Common Stock (right to buy) · traded 14 May 2020 · filed 18 May 2020
exercised options over 10,000 shares of Arrowhead Pharmaceuticals (a derivative holding)SEC Form 418 May 2020Common Stock (right to buy) · traded 14 May 2020 · filed 18 May 2020
exercised options over 15,000 shares of Arrowhead Pharmaceuticals (a derivative holding)SEC Form 418 May 2020Common Stock (right to buy) · traded 14 May 2020 · filed 18 May 2020
exercised options over 25,000 shares of Arrowhead Pharmaceuticals (a derivative holding)SEC Form 418 May 2020Common Stock (right to buy) · traded 14 May 2020 · filed 18 May 2020
exercised options over 7,000 shares of Arrowhead PharmaceuticalsSEC Form 418 May 2020Common Stock · traded 14 May 2020 · filed 18 May 2020
exercised options over 5,000 shares of Arrowhead PharmaceuticalsSEC Form 418 May 2020Common Stock · traded 14 May 2020 · filed 18 May 2020
exercised options over 15,000 shares of Arrowhead PharmaceuticalsSEC Form 418 May 2020Common Stock · traded 14 May 2020 · filed 18 May 2020
exercised options over 10,000 shares of Arrowhead PharmaceuticalsSEC Form 418 May 2020Common Stock · traded 14 May 2020 · filed 18 May 2020
exercised options over 15,000 shares of Arrowhead PharmaceuticalsSEC Form 418 May 2020Common Stock · traded 14 May 2020 · filed 18 May 2020
exercised options over 25,000 shares of Arrowhead PharmaceuticalsSEC Form 418 May 2020Common Stock · traded 14 May 2020 · filed 18 May 2020
▼ sold on the open market 29,900 shares of Arrowhead PharmaceuticalsSEC Form 413 May 2020Common Stock · traded 12 May 2020 · filed 13 May 2020
▼ sold on the open market 6,100 shares of Arrowhead PharmaceuticalsSEC Form 413 May 2020Common Stock · traded 12 May 2020 · filed 13 May 2020
acquired or disposed of, other 46,666 shares of Armata Pharmaceuticals (a derivative holding)SEC Form 414 February 2020Warrant to Purchase Common Stock · traded 9 May 2019 · filed 14 February 2020
was granted 8,000 shares of Arrowhead PharmaceuticalsSEC Form 43 January 2020Common Stock · traded 1 January 2020 · filed 3 January 2020
▼ sold on the open market 100,000 shares of Arrowhead PharmaceuticalsSEC Form 411 September 2019Common Stock · traded 9 September 2019 · filed 11 September 2019
▼ sold on the open market 85,000 shares of Arrowhead PharmaceuticalsSEC Form 411 September 2019Common Stock · traded 11 September 2019 · filed 11 September 2019
was granted 27,383 shares of Armata Pharmaceuticals (a derivative holding)SEC Form 424 May 2019Stock Option (Right to Buy) · traded 22 May 2019 · filed 24 May 2019
was granted 36,000 shares of Arrowhead PharmaceuticalsSEC Form 43 January 2019Common Stock · traded 1 January 2019 · filed 3 January 2019
▲ bought on the open market 5,757 shares of AmpliPhi BiosciencesSEC Form 426 March 2018Common Stock · traded 29 June 2017 · filed 26 March 2018
▲ bought on the open market 105,015 shares of AmpliPhi BiosciencesSEC Form 426 March 2018Common Stock · traded 19 September 2017 · filed 26 March 2018
▲ bought on the open market 181,820 shares of AmpliPhi BiosciencesSEC Form 426 March 2018Common Stock · traded 22 March 2018 · filed 26 March 2018
was granted 30,000 shares of Arrowhead PharmaceuticalsSEC Form 43 January 2018Common Stock · traded 1 January 2018 · filed 3 January 2018
was granted 10,900 shares of AmpliPhi Biosciences (a derivative holding)SEC Form 412 September 2017Stock Option (Right to Buy) · traded 7 September 2017 · filed 12 September 2017
was granted 80,000 shares of Arrowhead PharmaceuticalsSEC Form 44 January 2017Common Stock · traded 1 January 2017 · filed 4 January 2017
was granted 30,000 shares of Arrowhead ResearchSEC Form 44 January 2016Common Stock · traded 1 January 2016 · filed 4 January 2016
was granted 12,800 shares of AmpliPhi Biosciences (a derivative holding)SEC Form 423 September 2015Stock Option (right to buy) · traded 21 September 2015 · filed 23 September 2015
was granted 30,000 shares of Arrowhead ResearchSEC Form 46 March 2015Common Stock · traded 4 March 2015 · filed 6 March 2015
was granted 15,000 shares of Arrowhead ResearchSEC Form 410 February 2014Common Stock · traded 6 February 2014 · filed 10 February 2014
was granted 7,000 shares of Arrowhead Research (a derivative holding)SEC Form 424 September 2013Stock Option · traded 21 September 2013 · filed 24 September 2013
was granted 5,000 shares of Arrowhead Research (a derivative holding)SEC Form 48 May 2013Stock Option · traded 6 May 2013 · filed 8 May 2013
was granted 15,000 shares of Arrowhead Research (a derivative holding)SEC Form 41 April 2013Stock Option · traded 21 March 2013 · filed 1 April 2013
was granted 15,000 shares of Arrowhead Research (a derivative holding)SEC Form 425 March 2013Stock Option · traded 21 March 2013 · filed 25 March 2013
was granted 10,000 shares of Arrowhead Research (a derivative holding)SEC Form 42 October 2012Stock Option · traded 28 September 2012 · filed 2 October 2012
exercised options over 2,800 shares of Poniard Pharmaceuticals (a derivative holding)SEC Form 427 March 2012Restricted Stock Units · traded 26 March 2012 · filed 27 March 2012
exercised options over 2,800 shares of Poniard PharmaceuticalsSEC Form 427 March 2012Common Stock · traded 26 March 2012 · filed 27 March 2012
▼ sold on the open market 1,599 shares of Poniard PharmaceuticalsSEC Form 427 March 2012Common Stock (PARD) · traded 27 March 2012 · filed 27 March 2012
was granted 15,000 shares of Arrowhead Research (a derivative holding)SEC Form 421 February 2012Stock Option · traded 16 February 2012 · filed 21 February 2012
exercised options over 12,019 shares of Poniard Pharmaceuticals (a derivative holding)SEC Form 417 February 2012Restricted Stock Units · traded 15 February 2012 · filed 17 February 2012
exercised options over 12,019 shares of Poniard PharmaceuticalsSEC Form 417 February 2012Common Stock · traded 15 February 2012 · filed 17 February 2012
▼ sold on the open market 6,346 shares of Poniard PharmaceuticalsSEC Form 417 February 2012Common Stock (PARD) · traded 16 February 2012 · filed 17 February 2012
▼ sold on the open market 45,140 shares of Poniard PharmaceuticalsSEC Form 414 April 2011Common Stock (PARD) · traded 13 April 2011 · filed 14 April 2011
exercised options over 112,000 shares of Poniard Pharmaceuticals (a derivative holding)SEC Form 412 April 2011Restricted Stock Units · traded 9 April 2011 · filed 12 April 2011
exercised options over 112,000 shares of Poniard PharmaceuticalsSEC Form 412 April 2011Common Stock · traded 9 April 2011 · filed 12 April 2011
was granted 224,000 shares of Poniard Pharmaceuticals (a derivative holding)SEC Form 415 March 2011Restricted Stock Units · traded 14 March 2011 · filed 15 March 2011
was granted 480,770 shares of Poniard Pharmaceuticals (a derivative holding)SEC Form 416 February 2011Restricted Stock Units · traded 15 February 2011 · filed 16 February 2011
was granted 7,500 shares of Poniard PharmaceuticalsSEC Form 43 August 2010Common Stock (PARD) · traded 30 July 2010 · filed 3 August 2010
was granted 50,000 shares of Targeted Genetics Corp /wa/SEC Form 42 June 2010Common Stock · traded 27 May 2010 · filed 2 June 2010
was granted 7,500 shares of Poniard PharmaceuticalsSEC Form 421 April 2010Common Stock · traded 20 April 2010 · filed 21 April 2010
was granted 500,000 shares of Poniard Pharmaceuticals (a derivative holding)SEC Form 48 February 2010Stock Option · traded 5 February 2010 · filed 8 February 2010
was granted 60,000 shares of Targeted Genetics Corp /wa/ (a derivative holding)SEC Form 42 June 2009Stock Option (right to buy) · traded 29 May 2009 · filed 2 June 2009
was granted 10,000 shares of Targeted Genetics Corp /wa/SEC Form 419 May 2008Common Stock · traded 15 May 2008 · filed 19 May 2008
was granted 10,000 shares of Targeted Genetics Corp /wa/SEC Form 421 May 2007Common Stock · traded 17 May 2007 · filed 21 May 2007
was granted 20,000 shares of Targeted Genetics Corp /wa/ (a derivative holding)SEC Form 410 May 2006Stock Option (right to buy) · traded 8 May 2006 · filed 10 May 2006

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.